Drug Profile
CLBS 14
Alternative Names: Adult stem cell therapy for no-option refractory disabling angina - Lisata Therapeutics; CD34+ autologous stem cell therapy - Lisata Therapeutics/Takeda; CD34+ cell therapy - Lisata Therapeutics/Takeda; CLBS14; CLBS14-NORDA; CLBS14-RfA; OLOGOLatest Information Update: 26 Sep 2022
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Developer Lisata Therapeutics; Takeda
- Class Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Angina pectoris; Peripheral vascular disorders